Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Nature

• Publication date

  2005-04-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature03445PMID 15829967
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase.

  2005cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• A FlashPlate Assay for the Identification of PARP-1 Inhibitors

  2003cited by this paper
• A subset of ATM‐ and ATR‐dependent phosphorylation events requires the BRCA1 protein

  2003cited by this paper
• Phosphorylation of Histone H2AX and Activation of Mre11, Rad50, and Nbs1 in Response to Replication-dependent DNA Double-strand Breaks Induced by Mammalian DNA Topoisomerase I Cleavage Complexes*

  2003cited by this paper
• Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein.

  2003cited by this paper
• Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.

  2003cited by this paper
• Breast and ovarian cancer.

  2003cited by this paper
• The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.

  2002cited by this paper
• Brca2 (XRCC11) Deficiency Results in Radioresistant DNA Synthesis and a Higher Frequency of Spontaneous Deletions

  2002cited by this paper
• DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells.

  2001cited by this paper
• DNA repair: The replication connection

  2001cited by this paper
• Genome maintenance mechanisms for preventing cancer

  2001cited by this paper
• Mutation in Brca2 stimulates error‐prone homology‐directed repair of DNA double‐strand breaks occurring between repeated sequences

  2001cited by this paper
• BRCA2 is required for homology-directed repair of chromosomal breaks.

  2001cited by this paper
• The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin*

  2000cited by this paper
• DNA recombination: the replication connection.

  1999cited by this paper
• Involvement of poly(ADP-ribose) polymerase in base excision repair.

  1999cited by this paper
• Brca1 controls homology-directed DNA repair.

  1999cited by this paper
• Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.

  1999cited by this paper
• PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase*

  1999cited by this paper
• The 193-Kd Vault Protein, Vparp, Is a Novel Poly(Adp-Ribose) Polymerase

  1999cited by this paper
• PARP is important for genomic stability but dispensable in apoptosis.

  1997cited by this paper

• Replication Stress in Cancer: Mechanistic Insights and Therapeutic Opportunities for Radiosensitization

  2026cites this paper
• Discovery of Novel and Potent Dual PARP1/ERK Inhibitors as a Promising Strategy for Cancer Therapy.

  2026cites this paper
• DNA-damaging combination treatments impose genotype-specific constraints on hypermutator evolvability

  2026cites this paper
• Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer.

  2026cites this paper
• Harnessing DNA polymerase beta defect enhances synthetic lethality and treatment response in gastric cancer cells: implication for immunotherapy

  2026cites this paper
• Tumor metabolic adaptation induced by L-asparaginase reveals a vulnerability to PARP1/2 inhibitor in B-cell lymphomas.

  2026cites this paper
• APOBEC3B enhances the efficacy of PARP inhibitors in elimination of ovarian cancer stem cell

  2026cites this paper
• Yeast as a Platform to Dissect Poly(ADP-Ribose) Polymerase Function from Magnaporthe oryzae and Evaluate PARP Inhibitors.

  2026cites this paper
• Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation.

  2026cites this paper
• Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance

  2026cites this paper
• Quantitative analysis of genetic interactions in human cells from genome-wide CRISPR-Cas9 screens

  2026cites this paper
• A patent review of DNA polymerase theta (Polθ) targeted therapies (2019–2025)

  2026cites this paper
• Molidustat Targets a Synthetic Lethal Vulnerability in APC-Mutant Colorectal Cancer through GSTP1 and PHD2 Co-Inhibition

  2026cites this paper
• PROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity.

  2026cites this paper
• Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer

  2026cites this paper
• NSMF modulates replication stress to facilitate colorectal cancer progression

  2026cites this paper
• Targeting thymine DNA glycosylase induces synthetic lethality in p53-deficient cancers.

  2026cites this paper
• Analysis of Combinatorial Knockout CRISPR Screens with GRAPE: Genetic interaction Regression Analysis of Pairwise Effects

  2026cites this paper
• Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.

  2026cites this paper
• Design and synthesis of c-Met/PARP dual-target inhibitors for the treatment of BRCA wild-type TNBC.

  2026cites this paper
• Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination–proficient prostate cancer

  2026cites this paper
• A pharmacokinetic-pharmacodynamic/toxicodynamic model framework for PARP inhibitor combination therapy with DNA-damaging chemotherapeutics

  2026cites this paper
• The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition

  2026cites this paper
• CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC

  2026cites this paper
• WRN structural flexibility showcased through fragment-based lead discovery of inhibitors

  2026cites this paper
• Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study

  2026cites this paper
• Correlation of BRCA and homologous recombination deficiency status with clinical and survival outcomes in patients with advanced-stage ovarian cancer undergoing frontline therapy.

  2026cites this paper
• Is it feasible for CDKs inhibitors to herald a new era in tackling the low sensitivity and drug resistance associated with PARP inhibitors?

  2026cites this paper
• Exploiting synthetic lethality in epithelial ovarian cancer: multi-dimensional approaches beyond DNA damage repair.

  2026cites this paper
• Synthesis and evaluation of boron-containing heterocycles as drug candidates: Benzoxazaborinins as PARP inhibitors

  2026cites this paper
• A Multifunctional Prodrug with the DNA Damage Amplification Effect for Inducing Immunogenic Cell Death.

  2026cites this paper
• PARP1 and PARP2 are dispensable for DNA repair by microhomology-mediated end-joining at double-ended DSBs

  2026cites this paper
• Resveratrol potentiates chemotherapeutic efficacy of olaparib in MCF7 human breast cancer cells by inducing apoptosis.

  2026cites this paper
• AI-aided virtual screening and biological evaluation for discovering new potential poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors.

  2026cites this paper
• Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis

  2026cites this paper
• Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption

  2026cites this paper
• Therapeutic synergies that overcome carboplatin resistance in triple-negative breast cancer.

  2026cites this paper
• Synergistic Cellular Toxicity from Inhibition of Poly(ADP-ribose) Glycohydrolase (PARG) and Ubiquitin-Specific Protease 1 (USP1).

  2026cites this paper
• Impact of ionizing radiation and low-energy electrons on DNA functionality: radioprotection and radiosensitization potential of natural products

  2025cites this paper
• PARP inhibitors elicit a cellular senescence mediated inflammatory response in homologous recombination proficient cancer cells

  2025cites this paper
• Prognosis and Therapy of Ovarian Cancer: Part 2 – the Shifting Landscape of Medical Treatment in Ovarian Cancer

  2025cites this paper
• Anaplastic Lymphoma Kinase Inhibition Therapy for Hereditary Neuroblastoma

  2025cites this paper
• Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Ter: A Case Report

  2025cites this paper
• [Aurora-A overexpression promotes cervical cancer cell invasion and metastasis by activating the NF-κBp65/ARPC4 signaling axis].

  2025cites this paper
• Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells

  2025cites this paper
• Clinical differences among the PARP inhibitors in the first-line treatment of advanced-stage ovarian carcinoma

  2025cites this paper
• Integrating machine learning driven virtual screening and molecular dynamics simulations to identify potential inhibitors targeting PARP1 against prostate cancer

  2025cites this paper
• CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance

  2025cites this paper
• Exploration of Traditional Chinese Medicine Comprehensive Treatment of Triple Negative Breast Cancer Based on Molecular Pathological Mechanism

  2025cites this paper
• Employing a Highly Potent Fluorescence Probe to Discover a Poly (Adenosine Diphosphate‐ribose) Polymerases‐1/2 Binder and the Complex Structures Analysis

  2025cites this paper
• Targeting Poly (ADP-ribose) polymerase-1 (PARP-1) for DNA repair mechanism through QSAR-based virtual screening and MD simulation

  2025cites this paper
• Steroid‐Modulated Transcription Synergistically Forms DNA Double‐Strand Breaks With Topoisomerase II Inhibitor

  2025cites this paper
• Chemical inhibition of RPA gap protection sensitizes BRCA1-deficient cancers to PARP inhibition

  2025cites this paper
• Recent advances in the synthesis of poly (ADP-ribose).

  2025cites this paper
• Genetic characterization of BRCA1 and BRCA2 variants in cancer and high-risk family screening cohorts in the UAE population

  2025cites this paper
• The treatment of breast cancer in the era of precision medicine

  2025cites this paper
• Modulating NPC1L1 to Potentiate PARP Inhibitor-Induced Ferroptosis and Immune Response in Triple-Negative Breast Cancer

  2025cites this paper
• Computational design of PARP-1 inhibitors: QSAR, molecular docking, virtual screening, ADMET, and molecular dynamics simulations for targeted drug development

  2025cites this paper
• Synergistic enhancement of PARP inhibition via small molecule UNI66-mediated suppression of BRD4-dependent transcription of RAD51 and CtIP

  2025cites this paper
• The deubiquitination-PARylation positive feedback loop of the USP10-PARP1 axis promotes DNA damage repair and affects therapeutic efficacy of PARP1 inhibitor

  2025cites this paper
• Targeting DNA damage sensors for cancer therapy.

  2025cites this paper
• Joining of DNA breaks- interplay between DNA ligases and poly (ADP-ribose) polymerases.

  2025cites this paper
• Engaging an engineered PARP-2 catalytic domain mutant to solve the complex structures harboring approved drugs for structure analyses.

  2025cites this paper
• Shedding LIGHT on the changing landscape of poly‐ADP ribose polymerase inhibitors in ovarian cancer

  2025cites this paper
• Pimitespib, an HSP90 Inhibitor, Enhances the Efficacy of PARP Inhibitors in PARP Inhibitor‐Insensitive Breast Cancer Cells

  2025cites this paper
• PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapy.

  2025cites this paper
• Dynamic crosstalk between amino acid metabolism and cancer drug efficacy: From mechanisms to therapeutic opportunities

  2025cites this paper
• PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor.

  2025cites this paper
• Germline pathogenic variants in DNA repair pathways: a key feature in a significant subset of translocation-associated sarcomas

  2025cites this paper
• The Influence of Homologous Recombination Repair on Temozolomide Chemosensitivity in Gliomas.

  2025cites this paper
• Potential candidates for adjuvant olaparib treatment in operable breast cancer patients with germline BRCA1/2 pathogenic variants after neoadjuvant chemotherapy

  2025cites this paper
• Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy

  2025influential citation
• AmNA‐Modified Antisense Oligonucleotide Targeting MCM8 as a Cancer‐Specific Chemosensitizer for Platinum Compounds

  2025cites this paper
• Signaling pathway dysregulation in breast cancer

  2025cites this paper
• Assessing PARP trapping dynamics in ovarian cancer using a CRISPR-engineered FRET biosensor

  2025cites this paper
• Trabectedin Induces Synthetic Lethality via the p53-Dependent Apoptotic Pathway in Ovarian Cancer Cells Without BRCA Mutations When Used in Combination with Niraparib

  2025cites this paper
• Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment

  2025cites this paper
• [Prophylactic breast surgery: The role of DIEP (Deep Inferior Epigastric)].

  2025cites this paper
• Research Progress of PARP Inhibitors in Maintenance Therapy of Ovarian Cancer

  2025cites this paper
• Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.

  2025cites this paper
• The Development of ATM Inhibitors in Cancer Therapy

  2025cites this paper
• Harnessing p53 for targeted cancer therapy: new advances and future directions

  2025cites this paper
• Evaluative Methodology for HRD Testing: Development of Standard Tools for Consistency Assessment

  2025cites this paper
• Inhibition of the STAT3/Fanconi anemia axis is synthetic lethal with PARP inhibition in breast cancer

  2025cites this paper
• Novel clinical potential of poly (ADP‑ribose) polymerase inhibitors in triple‑negative breast cancer: Mechanistic insights and clinical applications (Review)

  2025cites this paper
• Targeting dePARylation in cancer therapy.

  2025cites this paper
• Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review

  2025cites this paper
• Harnessing STING Signaling and Natural Killer Cells overcomes PARP Inhibitor Resistance in Homologous Recombination Deficient Breast Cancer.

  2025cites this paper
• Deciphering the mechanisms of PARP inhibitor resistance in prostate cancer: Implications for precision medicine.

  2025cites this paper
• Modulation of OGG1 enzymatic activities by small molecules, promising tools and current challenges.

  2025cites this paper
• Assessment of safety of niraparib maintenance therapy in epithelial ovarian cancer: an updated systematic review and meta-analysis of randomized control trials

  2025cites this paper
• TAOK1 promotes filament formation in HR repair through phosphorylating USP7

  2025cites this paper
• Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer.

  2025cites this paper
• The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo

  2025cites this paper
• Oncogenic properties of wild-type DNA repair gene FANCA in breast cancer

  2025cites this paper
• Delivering on the Promise of Precision Oncology in Prostate Cancer: Prediagnostic Strategies, Postdiagnostic Applications, and Future Directions. A Narrative Review

  2025cites this paper
• DNA damage response in cancer: New treatment strategies

  2025cites this paper
• Discovery of a Novel [6-6-5-5-6] Pentacyclic Tetrahydrocyclopentaphthalazinone as a Promising PARP Inhibitor Scaffold.

  2025cites this paper
• Cancer vulnerabilities exposed by finding interactions among DNA repair factors.

  2025cites this paper
• D-bait: A siDNA for regulation of DNA-protein kinases against DNA damage and its implications in cancer.

  2025cites this paper